Resolution: standard / high
Figure 3.
Survival estimates of infliximab before and after the marketing authorization of etanercept
(p < 0.001).
Gomez-Reino et al. Arthritis Research & Therapy 2006 8:R29 doi:10.1186/ar1881
Download authors' original image